What is Accumetrics?
Accumetrics is dedicated to improving the quality of care for patients receiving antiplatelet treatments by offering industry-leading diagnostic tests for rapid platelet function assessment. The company's flagship VerifyNow System is a pioneering, user-friendly platform designed to help clinicians gauge an individual's response to various antiplatelet agents. This system addresses all major antiplatelet drugs, including those for aspirin, P2Y12 inhibitors like prasugrel and clopidogrel, and GP IIb/IIIa inhibitors such as ReoPro and Integrilin, providing crucial data for informed treatment decisions.
How much funding has Accumetrics raised?
Accumetrics has raised a total of $6M across 1 funding round:
Private Equity
$6M
Private Equity (2013): $6M with participation from SightLine Partners, LLC, Essex Woodlands Health Ventures, and RiverVest Venture Partners, LLC
Key Investors in Accumetrics
SightLine Partners, LLC
SightLine Partners is an investment firm that likely focuses on providing capital and strategic guidance to companies across various sectors, aiming to drive growth and enhance value through their investment strategies.
Essex Woodlands Health Ventures
EW Healthcare Partners is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on driving positive change in healthcare while achieving high returns. The firm partners with experienced management teams in the pharmaceuticals, MedTech, and tech-enabled services sectors, providing capital and strategic guidance to accelerate business growth.
RiverVest Venture Partners, LLC
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs. The firm aims to enhance patient lives, support entrepreneurs, and gain the trust of investors through its commitment to science, strategy, and innovation.
What's next for Accumetrics?
The substantial enterprise-level funding and recent strategic investment signal a strong growth trajectory for Accumetrics. This capital infusion is expected to fuel further development and market expansion of its diagnostic solutions, reinforcing its position in the competitive MedTech landscape. The company is poised to enhance its offerings and reach, solidifying its commitment to advancing platelet function diagnostics and improving patient outcomes globally.
See full Accumetrics company page
